| 1950 |
- Hitachi Chemical Co., Ltd. (as Chemiphar was formerly known) is set up
|
| 1951 |
- Hatagaya Factory opens in Shibuya-ku, Tokyo
|
| 1957 |
- Starts importing pharmaceuticals from Italy
- Head office moves to Bunkyo-ku Tokyo
|
| 1960 |
- Soka Factory opens in Misato City, Saitama Prefecture
|
| 1969 |
- Nihon Pharmaceutical Industry Co., Ltd. (NPI) becomes an affiliated company
|
| 1970 |
- Company changes name to Nippon Chemiphar Co., Ltd.
|
| 1971 |
- Listed on Tokyo Stock Exchange (Second Section)
|
| 1973 |
- Sets up R&D facility in Soka Factory
|
| 1975 |
- Head office moved to Chiyoda-ku, Tokyo (current location)
|
| 1976 |
- Listed on Tokyo Stock Exchange (First Section)
- Starts diagnostics business
- Establishes Japan Sopharchim Co., Ltd. (currently an affiliated company)
|
| 1977 |
- Establishes Ibaraki Factory in Makabe-gun, Ibaraki Prefecture (NPI's current Tsukuba Factory)
|
| 1983 |
- Establishes Shapro Inc., enters cosmetics and health-food market (currently a dormant company)
|
| 1986 |
- Safety Research Institute for Chemical Compounds Co., Ltd. becomes a subsidiary
|
| 1988 |
- Launches Uralyt-U (soluble powder)
|
| 1992 |
|
| 1993 |
|
| 1995 |
|
| 2000 |
- Full-scale entry into generics business
|
| 2001 |
- Launches DiaPack2000 and Oriton IgE NC
|
| 2002 |
- Concludes comprehensive business alliance concluded with Ranbaxy Laboratories Limited (HQ in India)
|
| 2004 |
- Concludes business alliance with Nihon Chouzai Co., Ltd.
|
| 2005 |
- NC-2300 and NC-2400 are licensed out to overseas venture companies
- NPI becomes 50:50 joint venture of Chemiphar and Ranbaxy
|
| 2009 |
- Dissolves the comprehensive business alliance with Ranbaxy. NPI becomes a subsidiary of Chemiphar
|
| 2010 |
- NPI becomes a wholly owned Chemiphar subsidiary. Chemiphar spins off its Ibaraki Factory to NPI.
- Termination of business alliance with Nihon Chouzai Co., Ltd.
|
| 2012 |
|
| 2014 |
- New facility at NPI's Tsukuba factory comes on line
|
| 2015 |
- Establishes Nippon Chemiphar Vietnam Co., Ltd.(NC-VN)
|
| 2017 |
- NC-VN completes construction of a new plant in Binh Duang Province, Vietnam
- Establishes West Japan Distribution Center, resulting one base each in East and West Japan
|
| 2018 |
- NC-VN Vietnam factory starts exporting to Japan
|
| 2019 |
- Acquires approval for the manufacture and sale of PICOPREP from Ferring Pharmaceuticals Co., Ltd.
|
| 2020 |
- Launches DropScreen™
- Concludes a license agreement with Delta-Fly Pharma, Inc. for DFP-17729
- Acquires sales rights for Klaricid from Mylan EPD G.K.
- Delta-Fly Pharma begins phase Ⅰ clinical trial of DFP-17729 for pancreatic cancer
|
| 2021 |
- DFP-17729 moved to phase Ⅱa trial
- Concludes a collaborative research and development agreement and an option agreement for NC-2800 with Sumitomo Dainippon Pharma Co., Ltd. and begins phase 1 trial in July
| 2022 |
- Concludes a license agreement with Delta-Fly Pharma for DFP-14323
| 2023 |
- Nanjing Neiwa Faith and Chemiphar concludes license agreement for NC-2500 in China
- Concludes marketing license agreement for DropScreen with FUJIFILM Medical Co., Ltd.
|
| 2025 |
- Launches Glimepiride Tablet“NC” as the first authorized generic
|
|
|
